Genotype | Patients (n = 322) | Controls (AFBAC) (n = 622) | OR | 95% CI | p Value* | ||
---|---|---|---|---|---|---|---|
n | % | n | % | ||||
The susceptibility genotype includes S/S+S/s+N/S genotypes (table 3); the neutral genotype includes s/s+S/P+S/p+N/s+s/p+N/p genotypes (table 3); the protective genotype includes s/P+p/p+N/N+p/O+N/P+P/p+P/P genotypes (table 3). | |||||||
*Only statistically significant p values are shown. | |||||||
†By Fisher’s exact test. | |||||||
AFBAC, affected family based artificial controls; DQRA−/−, patients homozygous of the haplotypes not included DQRA+ or DERAA+ alleles. | |||||||
Susceptibility | 121 | 37.6 | 51 | 8.2 | 6.74 | 4.61 to 9.87 | <10−6 |
Neutral | 143 | 44.4 | 277 | 44.5 | 0.99 | 0.75 to 1.32 | |
Protective | 47 | 14.6 | 269 | 43.3 | 0.22 | 0.16 to 0.32 | <10−6 |
SE+/SE+ | 119 | 37.0 | 50 | 8.0 | 6.71 | 4.57 to 9.85 | <10−6 |
SE+/SE− | 142 | 44.1 | 267 | 42.9 | 1.05 | 0.79 to 1.39 | |
SE−/SE− | 61 | 18.9 | 305 | 49.0 | 0.24 | 0.17 to 0.34 | <10−6 |
DQ3+/+ | 47 | 14.6 | 15 | 2.4 | 6.92 | 3.68 to 13.17 | <10−6 |
DQ3+/DQ5+ | 71 | 22.0 | 35 | 5.6 | 4.74 | 3.02 to 7.47 | <10−6 |
DQ5+/+ | 17 | 5.3 | 17 | 2.7 | 1.98 | 0.95 to 4.14 | |
DQ3+/DERAA+ | 29 | 9.0 | 51 | 8.2 | 1.11 | 0.67 to 1.83 | |
DQ5+/DERAA+ | 15 | 4.7 | 55 | 8.8 | 0.50 | 0.27 to 0.94 | 0.028 |
DERAA+/DERAA+ | 4 | 1.2 | 24 | 3.9 | 0.31 | 0.10 to 0.96 | 0.016† |
DQRA+/+ | 135 | 41.9 | 67 | 10.8 | 5.98 | 4.21 to 8.50 | <10−6 |
DQRA+/DERAA+ | 44 | 13.7 | 106 | 17.0 | 0.77 | 0.52 to 1.15 | |
DQRA−/− | 32 | 9.9 | 117 | 18.8 | 0.48 | 0.31 to 0.74 | 0.00056 |